Rapid induction of orthotopic hepatocellular carcinoma in immune-competent rats by non-invasive ultrasound-guided cells implantation

BMC Gastroenterology

Volumn 10, Issue , 2010, Pages

  Chan, Hoi Hung ^a,b,d   Chu, Tian Huei ^a   Chien, Hsin Fan ^a   Sun, Cheuk Kwan ^c   Wang, E Ming ^a,b   Pan, Huay Ben ^b   Kuo, Hsiao Mei ^a   Hu, Tsung Hui ^c   Lai, Kwok Hung ^b,d   Cheng, Jiin Tsuey ^a   Tai, Ming Hong ^a,b  

^a NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^b KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; EPIRUBICIN; ANTINEOPLASTIC ANTIBIOTIC;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CANCER TRANSPLANTATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ECHOGRAPHY; FEASIBILITY STUDY; HISTOPATHOLOGY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LOW DRUG DOSE; MALE; NON INVASIVE PROCEDURE; NONHUMAN; NOVIKOFF HEPATOMA; RAT; SHORT COURSE THERAPY; SPRAGUE DAWLEY RAT; TUMOR VOLUME; ANIMAL; CELL LINE; CELL TRANSPLANTATION; DISEASE COURSE; DISEASE MODEL; IMMUNOCOMPETENCE; LIVER TUMOR; METHODOLOGY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CELL LINE; CELL LINE, TUMOR; CELL TRANSPLANTATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEASIBILITY STUDIES; IMMUNOCOMPETENCE; LIVER NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; ULTRASONOGRAPHY;

EID: 77954800949     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-10-83     Document Type: Article

References (39)

1. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002, 35(5 Suppl 2):S72-S78. 10.1097/00004836-200211002-00002, 12394209.
2. Trevisani F, D'Intino PE, Grazi GL, Caraceni P, Gasbarrini A, Colantoni A, Stefanini GF, Mazziotti A, Gozzetti G, Gasbarrini G, Bernardi M. Clinical and pathologic features of hepatocellular carcinoma in young and older Italian patients. Cancer 1996, 71(11):2223-2232.
3. Befeler AS, Di-Biscegle AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002, 122(6):1609-1619. 10.1053/gast.2002.33411, 12016426.
4. Bruix J, Llovet JM. HCC surveillance: who is the target population?. Hepatology 2003, 37(3):507-509. 10.1053/jhep.2003.50142, 12601346.
5. Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, Khin MW, Koo WH. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009, 10(11):1111-1118. 10.1016/S1470-2045(09)70241-4, 19880065.
6. Di Maio M, De Maio E, Perrone F, Pignata S, Daniele B. Hepatocellular carcinoma: systemic treatments. J Clin Gastroenterol 2002, 35(5 Suppl 2):S109-S114. 10.1097/00004836-200211002-00007, 12394214.
7. Armengol C, Tarafa G, Boix L, Solé M, Queralt R, Costa D, Bachs O, Bruix J, Capellá G. Orthotopic Implantation of Human Hepatocellular carcinoma in mice Analysis of tumor progression and establishment of the BCLC-9 cell line. Clin Cancer Res 2004, 10(6):2150-2157. 10.1158/1078-0432.CCR-03-1028, 15041736.
8. Schmitz V, Tirado-Ledo L, Tiemann K, Raskopf E, Heinicke T, Ziske C, González-Carmona MA, Rabe C, Wernert N, Prieto J, Qian C, Sauerbruch T, Caselmann WH. Establishment of an orthotopic tumor model for hepatocellular carcinoma and non-invasive in vivo tumor imaging by high resolution ultrasound in mice. J Hepatol 2004, 40(5):787-791. 10.1016/j.jhep.2004.01.010, 15094226.
9. Meloni MF, Livraghi T, Filice C, Lazzaroni S, Calliada F, Perretti L. Radiofrequency ablation of liver tumors: the role of microbubble ultrasound contrast agents. Ultrasound Q 2006, 22(1):41-47.
10. Pohl J, Zuna I, Stremmel W, Rudi J. Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma. Chemotherapy 2001, 47(5):359-365. 10.1159/000048544, 11561139.
11. Zhu AX, Fuchs CS, Clark JW, Muzikansky A, Taylor K, Sheehan S, Tam K, Yung E, Kulke MH, Ryan DP. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist 2005, 10(6):392-398. 10.1634/theoncologist.10-6-392, 15967833.
12. Hamada A, Yamakado K, Nakatsuka A, Takaki H, Akeboshi M, Takeda K. Hepatic arterial infusion chemotherapy with use of an implanted port system in patients with advanced hepatocellular carcinoma: prognostic factors. J Vasc Interv Radiol 2004, 15(8):835-841.
13. Plosker GL, Epirubicin Faulds D. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 1993, 45(5):788-856. 10.2165/00003495-199345050-00011, 7686469.
14. Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000, 60(7):1878-1886.
15. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000, 105(8):R15-24. 10.1172/JCI8829, 517491, 10772661.
16. Lam T, Hetherington JW, Greenman J, Maraveyas A. From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials. Anticancer Drugs 2006, 17(2):113-121. 10.1097/00001813-200602000-00001, 16428928.
17. Yu J, Qiao L, Zimmermann L, Ebert MP, Zhang H, Lin W, Röcken C, Malfertheiner P, Farrell GC. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 2006, 43(1):134-143. 10.1002/hep.20994, 16374840.
18. Kan Z, Phongkitkarun S, Kobayashi S, Tang Y, Ellis LM, Lee TY, Charnsangavej C. Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model. Radiology 2005, 237(1):151-158. 10.1148/radiol.2363041293, 16183931.
19. Bertazzoli C, Rovero C, Ballerini L, Lux B, Balconi F, Antongiovanni V, Magrini U. Experimental systemic toxicology of 4'-epidoxorubicin, a new, less cardiotoxic anthracycline antitumor agent. Toxicol Appl Pharmacol 1985, 79(3):412-422. 10.1016/0041-008X(85)90139-5, 3862266.
20. Launchbury AP, Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 1993, 19(3):197-228. 10.1016/0305-7372(93)90036-Q, 8334677.
21. Abou-Alfa GK, Huitzil-Melendez FD, O'Reilly EM, Saltz LB. Current management of advanced hepatocellular carcinoma. Gastrointest Cancer Res 2008, 2(2):64-70. 2630820, 19259298.
22. Hahnfeldt P, Folkman J, Hlatky L. Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol 2003, 220(4):545-554. 10.1006/jtbi.2003.3162, 12623285.
23. Kerbel RS, Rak J, Kobayashi H, Man MS, StCroix B, Graham CH. Multicellular resistance: a new paradigm to explain aspects of acquired drug resistance of solid tumors. Cold Spring Harb Symp Quant Biol 1994, 59:661-672.
24. Jain RK. Delivery of novel therapeutic agents in tumors physiological barriers and strategies. J Natl Cancer Inst 1989, 81(8):570-576. 10.1093/jnci/81.8.570, 2649688.
25. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002, 29(6 Suppl 16):3-9.
26. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW, Weichselbaum RR. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999, 59(14):3374-3378.
27. Kamat AA, Kim TJ, Landen CN, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe RB, Coleman RL, Sood AK. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 2007, 67(1):281-288. 10.1158/0008-5472.CAN-06-3282, 17210709.
28. Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, Ghisini R, Sandri MT, Zorzino L, Nolè F, Viale G, Goldhirsch A. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 2006, 17(2):232-238. 10.1093/annonc/mdj066, 16322118.
29. Watanuki A, Ohwada S, Fukusato T, Makita F, Yamada T, Kikuchi A, Morishita Y. Prognostic significance of DNA topoisomerase II alpha expression in human hepatocellular carcinoma. Anticancer Res 2002, 22(2B):1113-1119.
30. Wong N, Yeo W, Wong WL, Wong NL, Chan KY, Mo FK, Koh J, Chan SL, Chan AT, Lai PB, Ching AK, Tong JH, Ng HK, Johnson PJ, To KF. TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer 2009, 124(3):644-652. 10.1002/ijc.23968, 19003983.
31. Edeline J, Raoul JL, Vauleon E, Guillygomac'h A, Boudjema K, Boucher E. Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: A retrospective study. World J Gastroenterol 2009, 15(6):713-716. 10.3748/wjg.15.713, 2655175, 19222095.
32. Takamatsu M, Matsuda T, Kawaguchi K, Ku Y. A complete response to one-shot hepatic arterial infusion of epirubicin in a patient with highly advanced hepatocellular carcinoma. Gan To Kagaku Ryoho 2007, 34(12):2102-2104.
33. Luo JJ, Yan ZP, Wang JH, Liu QX, Chen Y. Transhepatic arterial chemoembolization by epirubicin mixed with microspheres for hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 2007, 29(8):619-622.
34. Ishikawa T, Imai M, Kamimura H, Tsuchiya A, Togashi T, Watanabe K, Seki K, Ohta H, Yoshida T, Kamimura T. Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a pilot study. World J Gastroenterol 2007, 13(41):5465-5470.
35. Tanaka T, Ikeda M, Okusaka T, Ueno H, Morizane C, Ogura T, Hagihara A, Iwasa S. A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization. Cancer Chemother Pharmacol 2008, 61(4):683-688. 10.1007/s00280-007-0523-7, 17541589.
36. Yamashita S, Niinobu T, Nakagawa S, Amano M, Nishikawa Y, Hayashida H, Higaki N, Fujita M, Sakon M. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma providing a good QOL. Gan To Kagaku Ryoho 2006, 33(12):1928-1930.
37. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, Girardi L, Cillo U, Burra P, Giacomin A, Farinati F. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008, 103(4):914-921. 10.1111/j.1572-0241.2007.01712.x, 18177453.
38. Satti J. The emerging low-dose therapy for advanced cancers. Dose Response 2009, 7(3):208-220. 10.2203/dose-response.08-010.Satti, 2754535, 19809540.
39. Tang TC, Man S, Lee CR, Xu P, Kerbel RS. Impact of metronomic UFT/Cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. Neoplasia 2010, 12(3):264-274. 2838774, 20234820.